NASDAQ$BLFS

BioLife Solutions Inc · Q3 2022 earnings

Q3 2022 earnings · · Investor relations

Briefing

BioLife Solutions experienced revenue growth and positive adjusted EBITDA, driven by cell processing platform, despite supply chain challenges.

BioLife Solutions reported a 21% increase in revenue to $40.7 million for Q3 2022, with a strong performance from the cell processing platform. The company achieved positive adjusted EBITDA of $1.4 million, but adjusted the top of the 2022 revenue guidance range due to expected shipment delays related to supply-chain challenges impacting the cryogenic freezer product line.

  • Total revenue increased by 21% to $40.7 million compared to Q3 2021.
  • Cell Processing platform revenue increased by 57% over the same period in 2021.
  • Adjusted EBITDA was $1.4 million for the third quarter.
  • Tightened 2022 revenue guidance range reflecting year-over-year growth of 34% to 38% and organic growth of 37% to 40%.

Headline financials

Total Revenue

$40.7M

Previous: $33.8M+20.6%
EPS (adj)

-$0.15

Previous: -$0.19+21.1%
GAAP gross margin

31.0%

Previous: 25.0%+24.0%
Non-GAAP adjusted gross margin

34.0%

Previous: 28.0%+21.4%
GAAP operating loss

-$11.4M

Previous: -$11.2M-1.8%
Adjusted EBITDA

$1.4M

Previous: -$2.1M+166.7%
Capital Expenditures

-$5.94M

Previous: -$6.82M+12.9%
Free Cash Flow

-$15.9M

Previous: -$6.74M-135.8%
Net Income

-$9.96M

Previous: $79K-12703.8%
Operating Income

-$11.4M

Previous: -$11.2M-2.2%
Gross Profit

$12.6M

Previous: $8.45M+49.3%
Cash & Equivalents

$27M

Previous: $75.1M-64.0%
Total Assets

$488M

Previous: $559M-12.8%
Stock-Based Comp

$6.3M

No prior period

Revenue & EPS history

BioLife · Revenue · Quarterly

$40.7M

Q3 2022+20.6%vs Q3 2021
Beat estimate in 11 of 14 quarters(79%)
ActualEstimate

Revenue by segment

BioLife · $18.1M total across 1 segment · Q3 2022

  • Cell Processing platform
    $18.1M+57.4%

Forward guidance

Total revenue for 2022 is now expected to range from $160 million to $164 million, reflecting year-over-year growth of 34% to 38% and organic growth of 37% to 40%.

Tailwinds

  • Cell Processing platform: $67.0 million to $68.0 million, an increase of 49% to 51% over 2021 and organic growth of 42% to 43%.
  • Freezers and Thaw Systems platform: $66.0 million to $68.0 million, an increase of 17% to 20% over 2021 and organic growth of 8% to 13%.
  • Storage and Storage Services platform: $27.0 million to $28.0 million, a total and organic increase of 54% to 59% over 2021.
  • COVID-19 related revenue is expected to account for approximately 7% to 8% of total revenue.
  • BioLife expects positive full year adjusted EBITDA.

Headwinds

  • Modest reduction in the top of the range for Cell Processing platform is due to anticipated supply chain constraints.
  • Reduction for Freezers and Thaw Systems platform is due to anticipated supply chain constraints.
  • There continues to be some supply chain risk which could impact Freezers and Thaw Systems platform in Q1.
  • COVID-19 related revenue is expected to account for approximately 40% to 45% of the storage and storage services platform revenue.
  • Company does not provide guidance below the revenue line

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2022

Historical avgQ3 2022

+0.1%

Avg return

Earnings day

+0.8%

Avg return

5 days after

+4.3%

Avg return

30 days after

44%

22 / 50 earnings

Positive

+21.4%

Q3 2022

Best reaction

-34.5%

Q4 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+6.3%-2.4%+22.4%
Q4 2025+8.0%-8.1%-17.3%
Q3 2025-4.2%-4.1%-5.8%
Q2 2025+10.0%+24.4%+28.2%
Q1 2025+4.0%-1.4%+6.0%
Q4 2024+2.1%+7.6%-0.9%
Q3 2024-9.4%-21.0%+0.5%
Q2 2024+14.5%+20.3%+7.9%
Q1 2024+8.9%+25.0%+13.2%
Q4 2023+5.1%-0.5%+8.5%
Q3 2023-5.7%+3.1%+14.2%
Q2 2023-29.7%-34.9%-30.3%
Q1 2023-2.9%+3.5%+20.6%
Q4 2022+0.2%+2.7%-7.4%
Q3 2022+21.4%+14.1%-4.6%
Q2 2022+13.7%+15.7%+25.6%
Q1 2022-3.8%+1.6%+18.3%
Q4 2021-0.3%+0.9%-3.7%
Q3 2021-6.0%+5.2%-30.3%
Q2 2021-1.8%-3.9%+12.0%
Q1 2021-2.1%+4.8%+25.1%
Q4 2020+8.3%-7.8%-14.7%
Q3 2020+5.8%+0.8%+21.6%
Q2 2020+0.3%-5.4%+5.6%
Q1 2020+3.0%+10.5%+1.5%
Q4 2019-34.5%-36.7%-27.8%
Q3 2019-12.8%-8.8%-7.4%
Q2 2019-6.2%+1.1%+7.7%
Q1 2019-2.4%+4.5%+8.8%
Q4 2018+10.7%+19.4%+5.5%
Q3 2018+15.0%-8.0%-7.8%
Q2 2018-4.8%-1.0%+2.3%
Q1 2018-3.7%+7.6%+23.5%
Q4 2017-4.4%-10.2%+22.4%
Q3 2017+18.0%+21.6%+8.2%
Q2 2017+3.8%+8.2%+30.6%
Q1 2017+3.7%-1.4%+7.8%
Q4 2016-5.0%-9.5%-7.7%
Q3 2016+0.7%+2.7%+5.4%
Q2 2016-2.4%-7.7%-15.9%
Q3 2012+10.0%
Q1 2012+0.0%
Q4 2011+0.0%
Q3 2011+0.0%
Q2 2011-14.3%
Q1 2011+0.0%
Q4 2010-11.1%
Q3 2010+0.0%
Q2 2010+0.0%
Q1 2010+0.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro